Esmolol is used to quickly lower heart rate and blood pressure in patients during surgery or in emergency situations when the heart is beating too fast or irregularly.[2] Brevibloc is currently approved and in use across 21 indications[4].[1]
Brevibloc is one of 440 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
376 competitors in Atrial Fibrillation
Brevibloc
Calquence
Rituxan
Imbruvica
Versed
Anticoagulants
SGLT2 Inhibitor
Direct Anticoagulant
Low-Molecular-Weight Heparin
Liquamar
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Aug 15, 1988
BREVIBLOC
NDA NDA019386
Apr 7, 2016
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
NDA NDA205703
Sources